Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients

INTRODUCTION: Dimethyl fumarate (DMF) is a novel oral therapy used for the treatment of relapse-remitting multiple sclerosis (RRMS). In two 2-year pivotal Phase 3 trials in patients with RRMS, DMF significantly reduced disease activity based on both clinical and magnetic resonance imaging (MRI) find...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Andrew, Pike, James, Edwards, Michael R., Petrillo, Jennifer, Waller, John, Jones, Eddie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447554/
https://www.ncbi.nlm.nih.gov/pubmed/28093681
http://dx.doi.org/10.1007/s40120-016-0061-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447554/
https://www.ncbi.nlm.nih.gov/pubmed/28093681
http://dx.doi.org/10.1007/s40120-016-0061-5

Ejemplares similares